The DOI matches its Crossref record; 144 of the 144 references it cites were found in a registry or an index.
Genetics of Parkinson's disease
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Initial sequencing and analysis of the human genome
International Human Genome Sequencing Consortium, Whitehead Institute for Biomedical Research, C. F. G. R., Lander, E. S., Linton, L. M., Birren, B., Nusbaum, C., Zody, M. C., Baldwin, J., Devon, K., Dewar, K., et al. (2001) · Nature · doi:10.1038/35057062 · Cited by 24,216 · cited 1×
“The design and subsequent optimization of the GWAS approach only became feasible as a consequence of large-scale international consortium projects such as the Human Genome Project (112,113), the HapMap (114,115) and 1000 Genomes Projects (116).”
The sequence of the human genome
Venter, J. C., Adams, M. D., Myers, E. W., Li, P. W., Mural, R. J., Sutton, G. G., Smith, H. O., Yandell, M., Evans, C. A., Holt, R. A., et al. (2001) · Science · doi:10.1126/science.1058040 · Cited by 13,909
Staging of brain pathology related to sporadic Parkinson’s disease
Braak, H., Tredici, K. D., Rüb, U., de Vos, R. A. I., Jansen Steur, E. N. H., & Braak, E. (2003) · Neurobiology of Aging · doi:10.1016/s0197-4580(02)00065-9 · Cited by 10,777 · cited 5×
“However, other studies performing similar assessments in independent cross-sectional post-mortem cohorts have suggested that pathology progression may be different from the progression pattern described by Braak et al (5) in a substantial number of patients and, accordingy, suggested that the staging needs to be refin…”
BackgroundMethodInfluentialHughes, A. J., Daniel, S. E., Kilford, L., & Lees, A. J. (1992) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.55.3.181 · Cited by 10,378
Spillantini, M. G., Schmidt, M. L., Lee, V. M.-Y., Trojanowski, J. Q., Jakes, R., & Goedert, M. (1997) · Nature · doi:10.1038/42166 · Cited by 8,382
Mutation in the α-Synuclein Gene Identified in Families with Parkinson's Disease
Polymeropoulos, M. H., Lavedan, C., Leroy, E., Ide, S. E., Dehejia, A., Dutra, A., Pike, B., Root, H., Rubenstein, J., Boyer, R., et al. (1997) · Science · doi:10.1126/science.276.5321.2045 · Cited by 8,240
A map of human genome variation from population-scale sequencing.
The 1000 Genomes Project Consortium (2010) · Nature · doi:10.1038/nature09534 · Cited by 7,877
A haplotype map of the human genome
The International HapMap Consortium (2005) · Nature · doi:10.1038/nature04226 · Cited by 5,858
Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism
Kitada, T., Asakawa, S., Hattori, N., Matsumine, H., Yamamura, Y., Minoshima, S., Yokochi, M., Mizuno, Y., & Shimizu, N. (1998) · Nature · doi:10.1038/33416 · Cited by 5,227 · cited 1×
“Autosomal recessive homozygous or compound heterozygous loss-offunction mutations have been identified in three genes using traditional gene mapping approaches: PARK2 (parkin RBR E3 ubiquitin protein ligase, commonly known as Parkin) (48), PINK1 (PTEN induced putative kinase 1) (49), and PARK7 (parkinson protein 7, co…”
Backgroundα-Synuclein Locus Triplication Causes Parkinson's Disease
Singleton, A. B., Farrer, M., Johnson, J., Singleton, A., Hague, S., Kachergus, J., Hulihan, M., Peuralinna, T., Dutra, A., Nussbaum, R., et al. (2003) · Science · doi:10.1126/science.1090278 · Cited by 4,383
Cited by
Poewe, W., Seppi, K., Tanner, C. M., Halliday, G. M., Brundin, P., Volkmann, J., Schrag, A.-E., & Lang, A. E. (2017) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2017.13 · Cited by 5,415
Epidemiology of Parkinson’s disease
Tysnes, O.-B., & Storstein, A. (2017) · Journal of Neural Transmission · doi:10.1007/s00702-017-1686-y · Cited by 2,414
Advances in therapeutic applications of extracellular vesicles
Wiklander, O. P. B., Brennan, M. Á., Lötvall, J., Breakefield, X. O., & EL Andaloussi, S. (2019) · Science Translational Medicine · doi:10.1126/scitranslmed.aav8521 · Cited by 1,039
Parkinson’s Disease: From Pathogenesis to Pharmacogenomics
Cacabelos, R. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18030551 · Cited by 555
Park, J.-S., Davis, R. L., & Sue, C. M. (2018) · Current Neurology and Neuroscience Reports · doi:10.1007/s11910-018-0829-3 · Cited by 516
Parkinson's Disease and the Environment
Ball, N., Teo, W.-P., Chandra, S., & Chapman, J. (2019) · Frontiers in Neurology · doi:10.3389/fneur.2019.00218 · Cited by 480
di Domenico, A., Carola, G., Calatayud, C., Pons-Espinal, M., Muñoz, J. P., Richaud-Patin, Y., Fernandez-Carasa, I., Gut, M., Faella, A., Parameswaran, J., et al. (2019) · Stem Cell Reports · doi:10.1016/j.stemcr.2018.12.011 · Cited by 372
“Most PD cases are sporadic (85%), but familial mutations are accountable for 15% of patients (Lill, 2016).”
BackgroundEnhancing glycolysis attenuates Parkinson’s disease progression in models and clinical databases
Cai, R., Zhang, Y., Simmering, J. E., Schultz, J. L., Li, Y., Fernandez-Carasa, I., Consiglio, A., Raya, A., Polgreen, P. M., Narayanan, N. S., et al. (2019) · Journal of Clinical Investigation · doi:10.1172/jci129987 · Cited by 286
Hughes, C. D., Choi, M. L., Ryten, M., Hopkins, L., Drews, A., Botía, J. A., Iljina, M., Rodrigues, M., Gagliano, S. A., Gandhi, S., et al. (2019) · Acta Neuropathologica · doi:10.1007/s00401-018-1907-y · Cited by 177
Biological links between traumatic brain injury and Parkinson’s disease
Delic, V., Beck, K. D., Pang, K. C. H., & Citron, B. A. (2020) · Acta Neuropathologica Communications · doi:10.1186/s40478-020-00924-7 · Cited by 165
Singh, F., Prescott, A. R., Rosewell, P., Ball, G., Reith, A. D., & Ganley, I. G. (2021) · eLife · doi:10.7554/elife.67604 · Cited by 131
Cellular senescence in aging and age-related diseases: Implications for neurodegenerative diseases
(2020) · International Review of Neurobiology · doi:10.1016/bs.irn.2020.03.019 · Cited by 114
“Mitochondrial dysfunction has long been considered to be a key driver of PD (Lill, 2016; Park et al., 2018).”
BackgroundImpaired Mitophagy and Protein Acetylation Levels in Fibroblasts from Parkinson’s Disease Patients
Yakhine-Diop, S. M. S., Niso-Santano, M., Rodríguez-Arribas, M., Gómez-Sánchez, R., Martínez-Chacón, G., Uribe-Carretero, E., Navarro-García, J. A., Ruiz-Hurtado, G., Aiastui, A., Cooper, J. M., et al. (2019) · Molecular Neurobiology · doi:10.1007/s12035-018-1206-6 · Cited by 57
Choudhury, S. P., Bano, S., Sen, S., Suchal, K., Kumar, S., Nikolajeff, F., Dey, S. K., & Sharma, V. (2022) · npj Parkinson's Disease · doi:10.1038/s41531-022-00324-9 · Cited by 52
“Several factors are implicated in the preferential degradation of substantia nigra neurons in the brain during Parkinsonism, involving cytotoxic peptide buildup and aggregation (1), mitochondrial malfunction (2), and oxidative stress(204).”
BackgroundInfluentialPradhan, P., Majhi, O., Biswas, A., Joshi, V. K., & Sinha, D. (2020) · Cell Death & Disease · doi:10.1038/s41419-020-02942-8 · Cited by 44
ADORA2A rs5760423 and CYP1A2 rs762551 Polymorphisms as Risk Factors for Parkinson’s Disease
Siokas, V., Aloizou, A.-M., Tsouris, Z., Liampas, I., Liakos, P., Calina, D., Docea, A. O., Tsatsakis, A., Bogdanos, D. P., Hadjigeorgiou, G. M., et al. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10030381 · Cited by 29
Common signatures of differential microRNA expression in Parkinson’s and Alzheimer’s disease brains
Dobricic, V., Schilling, M., Farkas, I., Gveric, D. O., Ohlei, O., Schulz, J., Middleton, L., Gentleman, S. M., Parkkinen, L., Bertram, L., et al. (2022) · Brain Communications · doi:10.1093/braincomms/fcac274 · Cited by 22
Self-citationEmerging roles of leptin in Parkinson’s disease: Chronic inflammation, neuroprotection and more?
Regensburger, M., Rasul Chaudhry, S., Yasin, H., Zhao, Y., Stadlbauer, A., Buchfelder, M., & Kinfe, T. (2023) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2022.09.010 · Cited by 17
Metadata
- Authors
- Lill, C. M.
- Venue
- Molecular and Cellular Probes
- Publisher
- Elsevier BV
- Published
- 2016-12
- Volume
- 30
- Issue
- 6
- Pages
- 386-396
- ISSN
- 0890-8508 (ISSN-L)
- OpenAlex
- W2546834208
- Cited by
- 361
- References
- 144
- FWCI
- 27.89
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.